# Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy

> **NCT01356875** · PHASE2 · UNKNOWN · sponsor: **Basque Health Service** · enrollment: 42 (estimated)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** BSC
- **DRUG:** HIDRA/VPA

## Key facts

- **NCT ID:** NCT01356875
- **Lead sponsor:** Basque Health Service
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-09
- **Primary completion:** 2014-09
- **Final completion:** 2015-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2011-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01356875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01356875, "Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01356875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*